Tapentadol prolonged release for managing moderate to severe chronic neck pain with or without a neuropathic component

References

• Hoy DG, Protani M, De R, et al. The epidemiology of neck pain. Best Pract Res Rheumatol. 2010;24(6):783–792.
   PubMed Web of Science ®Google Scholar
• Hogg-Johnson S, van der Velde G, Carroll LJ, et al. The burden and determinants of neck pain in the general population: results of the bone and joint decade 2000–2010 task force on neck pain and its associated disorders. Spine (Phila Pa 1976). 2008;33(4 Suppl):S39–S51.
   PubMed Web of Science ®Google Scholar
• Teichtahl AJ, McColl G. An approach to neck pain for the family physician. Aust Fam Physician. 2013;42(11):774–777.
   PubMedGoogle Scholar
• Cohen SP, Hooten W. Advances in the diagnosis and management of neck pain. BMJ. 2017;358:j3221.
   PubMed Web of Science ®Google Scholar
• Coluzzi F, Fornasari D, Pergolizzi J, et al. From acute to chronic pain: tapentadol in the progressive stages of this disease entity. Eur Rev Med Pharmacol Sci. 2017;21(7):1672–1683.
   PubMed Web of Science ®Google Scholar
• Hofmann JF, Lal A, Steffens M, et al. Patient-relevant outcomes and health-related quality of life in patients with chronic, severe, noncancer pain treated with tapentadol prolonged release-using criteria of health technology assessment. J Opioid Management. 2016;12(5):323–331.
   PubMedGoogle Scholar
• Childs JD, Cleland JA, Elliott JM, et al. Neck pain: clinical practice guidelines linked to the international classification of functioning, disability, and health from the orthopaedic section of the American Physical Therapy Association. J Orthop Sports Phys Ther. 2008;38(9):A1–A34.
   PubMed Web of Science ®Google Scholar
• Billeci D, Coluzzi F. Tapentadol extended release for the management of chronic neck pain. JPR. 2017;10:495–505.
   Web of Science ®Google Scholar
• Machado GC, Maher CG, Ferreira PH, et al. Non-steroidal anti-inflammatory drugs for spinal pain: a systematic review and meta-analysis. Ann Rheum Dis. 2017;76(7):1269–1278.
   PubMed Web of Science ®Google Scholar
• Malfliet A, Kregel J, Cagnie B, et al. Lack of evidence for central sensitization in idiopathic, non-traumatic neck pain: a systematic review. Pain Physician. 2015;18(3):223–236.
   PubMed Web of Science ®Google Scholar
• Morlion B, Coluzzi F, Aldington D, et al. Pain chronification: what should a non-pain medicine specialist know? Curr Med Res Opin. 2018;34(7):1169–1178.
   PubMed Web of Science ®Google Scholar
• Mehra M, Hill K, Nicholl D, et al. The burden of chronic pain with and without a neuropathic component: a healthcare resource use and cost analysis. J Med Econ. 2012;15(2):245–252.
   PubMedGoogle Scholar
• Foster NE, Anema JR, Cherkin D, et al. Lancet Low Back Pain Series Working Group. Prevention and treatment of low back pain: evidence, challenges, and promising directions. Lancet. 2018;91(10137):2368–2383.
   Web of Science ®Google Scholar
• Kress HG. Tapentadol and its two mechanisms of action: is there a new pharmacological class of centrally-acting analgesics on the horizon? Eur J Pain. 2010;14(8):781–783.
   PubMed Web of Science ®Google Scholar
• Raffa RB, Elling C, Tzschentke TM. Does ‘strong analgesic’ equal ‘strong opioid’? Tapentadol and the concept of ‘µ-load. Adv Ther. 2018;35(10):1471–1484.
   PubMed Web of Science ®Google Scholar
• Pergolizzi JV, Jr, Breve F, Taylor R, Jr, et al. Considering tapentadol as a first-line analgesic: 14 questions. Pain Manag. 2017;7(4):331–339.
   PubMed Web of Science ®Google Scholar
• Coluzzi F, Billeci D, Maggi M, et al. Testosterone deficiency in non-cancer opioid-treated patients. J Endocrinol Invest. 2018;41(12):1377–1388.
   PubMed Web of Science ®Google Scholar
• Tzschentke TM, Folgering JH, Flik G, et al. Tapentadol increases levels of noradrenaline in the rat spinal cord as measured by in vivo microdialysis. Neurosci Lett. 2012;507(2):151–155.
   PubMed Web of Science ®Google Scholar
• VanDenKerkhof EG, Stitt L, Clark AJ, et al. Sensitivity of the DN4 in screening for neuropathic pain syndromes. Clin J Pain. 2018;34(1):30–36.
   PubMed Web of Science ®Google Scholar
• Vernon H, Mior S. The Neck Disability Index: a study of reliability and validity. J Manipulative Physiol Ther. 1991;14(7):409–415.
   PubMed Web of Science ®Google Scholar
• Cleland JA, Fritz JM, Whitman JM, et al. The reliability and construct validity of the Neck Disability Index and patient specific functional scale in patients with cervical radiculopathy. Spine (Phila Pa 1976). 2006;31(5):598–602.
   PubMed Web of Science ®Google Scholar
• Baron R, Jansen JP, Binder A, et al. Tolerability, safety, and quality of life with tapentadol prolonged release (PR) compared with oxycodone/naloxone PR in patients with severe chronic low back pain with a neuropathic component: a randomized, controlled, open-label, phase 3B/4 trial. Pain Pract. 2016;16(5):600–619.
   PubMed Web of Science ®Google Scholar
• Coluzzi F, Raffa RB, Pergolizzi J, et al. Tapentadol prolonged release for patients with multiple myeloma suffering from moderate-to-severe cancer pain due to bone disease. J Pain Res. 2015;8:229–238.
   PubMed Web of Science ®Google Scholar
• Steigerwald I, Müller M, Davies A, et al. Effectiveness and safety of tapentadol prolonged release for severe, chronic low back pain with or without a neuropathic pain component: results of an open-label, phase 3b study. Curr Med Res Opin. 2012;28(6):911–936.
   PubMed Web of Science ®Google Scholar
• Kelly MP, Anderson PA, Sasso RC, Riew KD. Preoperative opioid strength may not affect outcomes of anterior cervical procedures: a post hoc analysis of 2 prospective, randomized trials. SPI. 2015;23(4):484–489.
   Web of Science ®Google Scholar
• Marty M, Rozenberg S, Duplan B, Thomas P, Duquesnoy B, Allaert F, The Section Rachis de la Société Française de Rhumatologie. Quality of sleep in patients with chronic low back pain: a case-control study. Eur Spine J. 2008;17(6):839–844.
   PubMed Web of Science ®Google Scholar